SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix
SERB Pharmaceuticals has finalized its acquisition of development and commercialization rights to Idefirix (imlifidase) across Europe and MENA from Hansa Biopharma.
SERB Pharmaceuticals has completed its acquisition of the European and Middle East and North Africa rights to Idefirix (imlifidase) from Hansa Biopharma, the company announced, marking a significant expansion of SERB's rare disease portfolio in those regions.
Imlifidase, marketed as Idefirix, is a specialty biologic that holds regulatory approval in Europe. The transfer of development and commercialization rights from Hansa Biopharma to SERB positions the acquiring company as the primary commercial driver for the therapy across two major geographic territories.
Read more U.S. Auto Industry Braces for Uncertainty Over USMCA Deal Extension →
The deal underscores a broader trend of mid-size specialty pharmaceutical firms consolidating rights to approved rare-disease assets in international markets, where patient populations are often underserved and commercial competition remains limited. For SERB, gaining control over both development and commercialization functions gives the company direct influence over how Idefirix is launched, priced, and distributed across European and MENA healthcare systems.
For Hansa Biopharma, divesting these regional rights allows the Swedish biotech to streamline its commercial focus and potentially redeploy capital toward pipeline development or other strategic priorities, a common rationale behind such asset transfers in the specialty pharma sector.
The financial terms of the transaction were not disclosed in the announcement. Continue reading at GlobalNewswire.
